<?xml version='1.0' encoding='utf-8'?>
<document id="21228405"><sentence text="Drug-drug interaction study to assess the effects of multiple-dose pitavastatin on steady-state warfarin in healthy adult volunteers."><entity charOffset="67-79" id="DDI-PubMed.21228405.s1.e0" text="pitavastatin" /></sentence><sentence text="Warfarin, an antagonist of vitamin K, which inhibits clotting factor synthesis, is prescribed for thrombosis prophylaxis and treatment and is known to have a narrow therapeutic range"><entity charOffset="27-36" id="DDI-PubMed.21228405.s2.e0" text="vitamin K" /></sentence><sentence text=" Pitavastatin is a potent HMG-CoA reductase inhibitor"><entity charOffset="1-13" id="DDI-PubMed.21228405.s3.e0" text="Pitavastatin" /></sentence><sentence text=" In this study, the influence of multiple-dose pitavastatin (4 mg once daily) on steady-state warfarin pharmacodynamic and pharmacokinetic profiles was investigated in 24 healthy male participants whose international normalized ratio (INR) was maintained by individualized doses of warfarin"><entity charOffset="47-59" id="DDI-PubMed.21228405.s4.e0" text="pitavastatin" /><entity charOffset="282-290" id="DDI-PubMed.21228405.s4.e1" text="warfarin" /><pair ddi="false" e1="DDI-PubMed.21228405.s4.e0" e2="DDI-PubMed.21228405.s4.e0" /><pair ddi="false" e1="DDI-PubMed.21228405.s4.e0" e2="DDI-PubMed.21228405.s4.e1" /></sentence><sentence text=" The ratio of the least squares mean of prothrombin time and INR was 0" /><sentence text="989 (90% confidence interval [CI], 0" /><sentence text="955-1" /><sentence text="023) and 0" /><sentence text="993 (0" /><sentence text="956-1" /><sentence text="209), respectively (test: warfarin + pitavastatin; reference: warfarin only)"><entity charOffset="26-49" id="DDI-PubMed.21228405.s11.e0" text="warfarin + pitavastatin" /><entity charOffset="62-70" id="DDI-PubMed.21228405.s11.e1" text="warfarin" /><pair ddi="false" e1="DDI-PubMed.21228405.s11.e0" e2="DDI-PubMed.21228405.s11.e0" /><pair ddi="false" e1="DDI-PubMed.21228405.s11.e0" e2="DDI-PubMed.21228405.s11.e1" /></sentence><sentence text=" The geometric mean ratios of C(max) and AUC were 1" /><sentence text="034 (90% CI, 0" /><sentence text="994-1" /><sentence text="075) and 1" /><sentence text="066 (1" /><sentence text="035-1" /><sentence text="099), respectively, for R-warfarin and 1"><entity charOffset="24-34" id="DDI-PubMed.21228405.s18.e0" text="R-warfarin" /></sentence><sentence text="033 (0" /><sentence text="995-1" /><sentence text="073) and 1" /><sentence text="058 (1" /><sentence text="026-1" /><sentence text="092), respectively, for S-warfarin"><entity charOffset="24-34" id="DDI-PubMed.21228405.s24.e0" text="S-warfarin" /></sentence><sentence text=" Warfarin pharmacodynamic profiles and pharmacokinetic profiles did not differ between the warfarin monotherapy and the coadministration of pitavastatin and warfarin"><entity charOffset="140-152" id="DDI-PubMed.21228405.s25.e0" text="pitavastatin" /><entity charOffset="157-165" id="DDI-PubMed.21228405.s25.e1" text="warfarin" /><pair ddi="false" e1="DDI-PubMed.21228405.s25.e0" e2="DDI-PubMed.21228405.s25.e0" /><pair ddi="false" e1="DDI-PubMed.21228405.s25.e0" e2="DDI-PubMed.21228405.s25.e1" /></sentence><sentence text=" No drug-drug interaction between pitavastatin and warfarin was demonstrated"><entity charOffset="34-46" id="DDI-PubMed.21228405.s26.e0" text="pitavastatin" /></sentence><sentence text="" /></document>